Share Name Share Symbol Market Type Share ISIN Share Description
Bioquell LSE:BQE London Ordinary Share GB0004992003 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 597.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 29.19 3.28 11.60 51.5 133
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 597.00 GBX

Bioquell (BQE) Latest News

Real-Time news about Bioquell (London Stock Exchange): 0 recent articles
More Bioquell News
Bioquell Takeover Rumours

Bioquell (BQE) Discussions and Chat

Bioquell Forums and Chat

Date Time Title Posts
07/2/201910:54BQE helps fight MRSA1,183
29/10/200716:35Bioquell technology to kill SARS virus plus others.116
08/12/200316:43BQE - may benefit from Gov plan to fight hospital superbugs1

Add a New Thread

Bioquell (BQE) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Bioquell trades in real-time

Bioquell (BQE) Top Chat Posts

18bt: Price is good, but now I need to find another growth company with an undervalued share price. Perhaps ST will help again.
bountyhunter: A quick look at the results shows that "most of its revenues are generated from overseas customers" and "Bioquell's products and services are sold by wholly-owned Bioquell organisations in the UK, USA, France, Germany, Ireland, Singapore, China and through a network of international distributors" so BQE is not too dependent on UK NHS or private hospitals fortunately. Also it's encouraging that "with respect to profitability, the Board believes that the Company will exceed current market expectations for profit for the full year" so that may be driving the share price growth right now. I'll need to look into the details further but no time right now unfortunately! To find my FTSE thread just type FTSE into the EPIC code box at the top right of the page and you should find it (since no one is likely to check UKX).
bountyhunter: Looking back at the recent BQE results I am now thinking that the share price strength of late may be simply building on those "bug busting" results: Https://
countless: I am surprised this has bounced back as I cannot see how their expected turnover justifies the share price. I thought I would share the full email as I found it hard to fully understand without getting the books out to help!
bountyhunter: Clearly charting signals cannot be relied upon or if it was that easy we would all be very rich. In my experience some of the time they are right and some of the time they are wrong but there is a better chance of a signal being correct when the market cap is larger and there is more liquidity, although even then it wouldn't be wise to rely on charting signals alone, imho. Re EPS growth LSE gives 794% as the most recent figure which is almost identical to the ADVFN figure. Https:// Of course it would be difficult to maintain such a high figure this year and I'm not expecting or suggesting that but it may account for the share price rise since financials were reported.
bountyhunter: The half-yearly report out this morning looks pretty good to me... Financial highlights -- Total revenues including defence sales increased by 19% to GBP14.3 million (2016: GBP12.1 million); up 10% at constant currency rates. -- Bio-decontamination revenues increased by 27% to GBP14.0 million (2016: GBP11.1 million); up 17% at constant currency rates. -- Non-UK revenues amounted to GBP11.3 million (2016: GBP9.0 million) - 79% of total revenues (2016: 75%) -- Gross margin increased to 52% (2016: 46%) -- EBITDA increased 56% to GBP2.5 million (2016: GBP1.6 million) -- Profit before tax more than trebled to GBP1.4 million (2016: GBP0.4 million) -- Basic earnings per share were 5.5p (2016: 0.8p) -- Net cash of GBP11.8 million at 30 June 2017 (2016: GBP7.3 million) Ian Johnson, Chairman of Bioquell PLC, said: "I am pleased to report that after a number of years of little growth, total revenues increased by 19% in the half year and that our core bio-decontamination division produced strong revenue growth of 27%. Profitability improved as a result of a significant improvement in margins coupled with tight cost control. Management continues to seek ways to simplify and focus the business around the core bio-decontamination products and services driving higher margin sales and yielding higher quality earnings. Given the momentum in the business the Board believes that the Company's profit before taxation for the current financial year will exceed current market expectations" Http://
bountyhunter: Bed & ISA @148.4p - a good move by the FD... Http://
bountyhunter: buybacks to continue Http://
bangalorebob: Bioquell's EBITDA increased 14% to £1.6 million in the six months to the end of June and the group has now terminated its strategic review. Overall revenues declined by 3% to £12.1 million (2015: £12.5 million) but bio-decontamination revenues (excluding defence sales) rose by 8% to £11.1 million (2015: £10.3 million) and non-UK revenues amounted to £9.0 million (2015: £10.0 million) - representing 74% of total revenues. Gross margin increased to 46% (2015: 42%). Earnings per share were 0.8p (2015: 82.5p, 0.2p excluding the profit on disposal of TRaC). Following the completion of the June tender offer, £40.8 million of cash was returned to shareholders via a share buyback, leaving net cash of £7.3 million at 30 June, 2016 (2015: £47.7 million). Chairman Ian Johnson said: "Whilst overall revenues declined slightly as a result of lower defence sales compared with the first half of 2015, I am pleased to report that our bio-decontamination business grew by 8%. "Profitability improved as a result of our cost reduction programme - and management continues to seek further improvements in the financial performance of the business through greater focus on the international Life Sciences market and driving up the proportion of recurring revenues. "The board has now concluded the strategic review announced in 2015 and believes that Bioquell shareholders' interests would best be served by continuing to build a world class bio-decontamination business and focusing on further improving its financial performance. "Accordingly the management of the business will be restructured. I have become Executive Chairman and the current Chief Executive, Nick Adams, has stepped down. In addition, Jay LeCoque has joined the board of Bioquell in the new role of Commercial Director. "On behalf of all Bioquell shareholders I would like to thank Nigel Keen for his seven years as chairman. "I would also like to thank Nick Adams for his substantial contribution as chief executive. Under his leadership Bioquell has changed beyond all recognition from a low technology manufacturer of safety cabinets to a leader in specialist bio-decontamination. "The board is confident that the improved financial performance seen in the first half of the year will carry through to the full year." At 8:17am: (LON:BQE) Bioquell PLC share price was -8p at 145.5p
pavey ark: Much number crunching this morning as I tried to figure out if the current price is fair or a bit of an anomaly. Obviously the £2 return is good and adds to the cash pile I prefer at this time of year (sell in May and all that)but if you bought at c. 170p you would be paying 140p for the retained half of your purchase and this would value the company at just shy of £30m. Ignoring property and equipment but including current cash and inventory I get close to £10m for current assets. ( I don't usually include inventory in these calculation but we are up for sale and the value is such a small percentage of total t/o that it is unlikely to be "dead stock".I am assuming an slight increase in cash from profits in H1 ) If one simply looks at previous year(s) then the figures don't look great but the biggest single factor in valuing this company is the t/o , gross profit and admin costs. Although the profit last year was under £1m the sales and admin costs alone came to £9m with £1.5m in R and D. NB gross profit of over £11m. If we look on the sunny side and assume that things are improving, albeit not at a great pace, this trading improvement is likely to be overshadowed by cost reductions. If no bid is forthcoming then the savings made by the company and subsequent profit level will determine the share price but while BQE is still up for sale we must consider the cost savings that an acquiring company could achieve and therefore be prepared to pay. As I have said before, there's obviously not a long line of companies clamouring for BQE but perhaps they are in a narrow field. My figures suggest to me that even without a bid there is value here after the buy back. The bid prospects look to be in for free but my average price is c. 150p so happy with £2 for half and happy to hold remainder. Final thought, the company has said that any bid would likely be less than £2. If someone paid £2 they would be paying £42.7m so less might bring us in at less than £40m. If my current asset value is anything like accurate then the acquiring company is hardly straining to justify the purchase price given the cost saving that are up for grabs but this being said there has been no offer,so back to square one ?
Bioquell share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200926 18:48:59